nash
Nimbus Therapeutics receives $200 million payment from Gilead
November 2, 2016Research and Development Gilead Sciences, Nimbus Therapeutics, nash
Nimbus Therapeutics only signed a deal with Gilead Sciences back in April of this year and yet have already received …
Allergan expands NASH portfolio with $1.7 billion in acquisitions
September 21, 2016Research and Development, Sales and Marketing Akarna Therapeutics, Allergan, Tobira Therapeutics, acqusition, nash
Allergan has gone on a spending spree this week, snapping up clinical-stage biotech Tobira Therapeutics and privately-held Akarna Therapeutics for …
FDA fast tracks Shire’s SHP626 nonalcoholic steatohepatitis drug
July 29, 2016Research and Development FDA, SHP626, Shire, liver fibrosis, nash, volixibat, volxibat
The Food and Drug Administration (FDA) has granted Fast Track designation to Shire’s SHP626 (volixibat) treatment for patients suffering from …
Gilead acquires Phenex liver disease drugs
January 7, 2015Research and Development, Sales and Marketing Farnesoid X Receptor, Gilead, liver, nafld, nash, phenex
Gilead Sciences has acquired Phenex Pharmaceuticals’ development programme for the treatment of serious liver diseases. The US biopharma firm will …
GE and Takeda make liver pact
November 13, 2014Research and Development, Sales and Marketing GE Healthcare, Japan, Takeda, US, liver, nafld, nash
GE Healthcare and Takeda Pharmaceutical have joined forces to develop treatments which target liver conditions including non-alcoholic fatty liver disease …
Latest content
FibroFind appoints Lee Borthwick as CEO
